Clinical trials: Lipemia
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
HYPERTENSION, HYPERCHOLESTEROLEMIA
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
This 10-12 week study will provide data on the safety and efficacy of using 320 valsartan and 80 mg simvastatin together compared to using either one alone in lowering blood pressure and LDL cholesterol.
- Trial name
- NCT00171093
- Testing
- valsartan + simvastatin
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Novartis
Hypercholesterolemia
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
- Trial name
- NCT07634484
- Testing
- Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Kowa Company, Ltd.
Hypercholesterolemia, Cardiovascular Risk Factor
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
This clinical study aims to assess the efficacy of 6 weeks 2.5g dose of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Atherosclerosis
- Trial name
- OLALIP (NCT05594979)
- Testing
- TOTUM-070
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Hypercholesterolemia
EZETROL® Re-examination Study (MK0653-175)(COMPLETED)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of EZETROL® through collecting…
- Trial name
- NCT01070953
- Volunteers
- 4,467 people
- Sponsor
- Organon and Co
Hyperlipoproteinemia Type III
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high…
- Trial name
- NCT00145431
- Testing
- torcetrapib/atorvastatin, atorvastatin, fenofibrate
- Where
- 27 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Pfizer
Hyperlipidemia, Mixed Dyslipidemia
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in aduts with normal renal function or severe renal impairment or end-stage renal disease (ESRD)…
- Trial name
- NCT02275156
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Amgen
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01811472
- Testing
- LCQ908
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Hyperlipidemias
To Evaluate Safety and Effectiveness of RovatitanTab.
To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia
- Trial name
- NCT04398771
- Testing
- Rosuvastatin/Valsartan
- Volunteers
- 1,000 people
- Sponsor
- LG Chem
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
- Trial name
- NCT00134498
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 44 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Pfizer
Hypercholesterolemia, Familial Hypercholesterolemia
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a…
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia
- Trial name
- NCT00705211
- Testing
- Ezetimibe, Ezetimibe + other lipid-lowering medication(s)
- Volunteers
- 1,794 people
- Sponsor
- Organon and Co
Hypertension and Hyperlipidemia
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
- Trial name
- NCT03103256
- Testing
- YHP1701, YHR1703, YHR1704
- Where
- South Korea
- Volunteers
- 106 people
- Sponsor
- Yuhan Corporation
Hyperlipidemia
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255094
- Testing
- AK102
- Where
- China
- Volunteers
- 464 people
- Sponsor
- Akeso
Overweight, Obesity
Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk
The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
- Conditions
- Overweight, Obesity, Metabolic Syndrome, Healthy
- Trial name
- PINEAPPL (NCT06355544)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Integrative Phenomics
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
An open-label study of volanesorsen (ISIS 304801) administered subcutaneously to participants with FCS.
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Trial name
- NCT02658175
- Testing
- Volanesorsen
- Where
- 34 sites in United States, Brazil and 9 more
- Volunteers
- 68 people
- Sponsor
- Akcea Therapeutics
Hypercholesterolemia
Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product
To compare the pharmacokinetics (PK), and pharmacodynamics (PD) of single subcutaneous (SC) doses of 300 mg LIB003 Process 1 (P1) and Process 2 (P2) drug product in subjects with or without statin therapy
- Trial name
- NCT05234775
- Testing
- lerodalcibep
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- LIB Therapeutics LLC
Hyperlipoproteinemia Type I
Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
LPL (Lipoprotein Lipase) is an enzyme which plays an important role in the elimination of triglycerides (fat) and the clearance of dietary fat particles known as chylomicrons (CM) in the blood.
- Trial name
- NCT01447901
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Amsterdam Molecular Therapeutics
Hypercholesterolemia
Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia
A Multi-center, Open-label, Observational Study to evaluate the Efficacy and Safety of Pitavastatin/Ezetimibe after switching from Statin Monotherapy to Pitavastatin/Ezetimibe in patients with Hypercholesterolemia
- Trial name
- NCT07445542
- Where
- South Korea
- Volunteers
- 6,927 people
- Sponsor
- JW Pharmaceutical
Hypertriglyceridemia
Study of MAR001 in Adults With Metabolic Dysfunction
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
- Trial name
- NCT05896254
- Testing
- MAR001
- Where
- 2 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Marea Therapeutics
Hyperlipidemia
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a…
- Trial name
- LAPLACE (NCT01380730)
- Testing
- Evolocumab
- Where
- 100 sites in United States, Canada and 3 more
- Volunteers
- 631 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.